

CS Pharmaceuticals announces appointment of Roberto Lee as Non Executive Director

London, England, November 29, 2021, CS Pharmaceuticals Ltd. (CSP), a British speciality pharmaceutical company focused on first- and best-in-class speciality therapeutics and treatments for rare diseases in China, are pleased to announce the appointment of Roberto Lee as Non Executive Director.

Roberto Lee is SVP, Greater China for EVERSANA Services and has significant experience in healthcare in China. Prior to joining EVERSANA, Roberto was Managing Director of KDL within Shanghai Pharmaceutical Group (SPG), the 2nd largest healthcare distributor in China and one of the largest state-owned enterprises in China and revenues > \$25B USD and Fortune 500 company. Roberto joined SPG following its acquisition of Cardinal Health China (KDL) where he was Chief Commercial Officer “We are delighted to welcome Roberto Lee to the Board”, said Darren Mercer CEO of CSP. “Roberto’s deep knowledge and insights of the commercialisation of pharmaceutical products in China will be a huge asset to CSP as we look to accelerate our transition to a speciality pharma with sales and marketing infrastructure in China.”

“I am hugely excited to be joining CSP at this point in their growth cycle as they seek to accelerate the commercialisation of their product portfolio and look to build sales and marketing infrastructure in China”, said Roberto Lee. “The changes that are taking place in the China pharmaceutical market, especially the changes to reimbursement via the National Reimbursement Drug List and the prospect of Orphan Drug legislation, means that CSP has tremendous potential to create a commercially focussed speciality pharma company in China.”

About CS Pharmaceuticals

CS Pharmaceuticals (CSP) is a British multinational pharmaceutical company focused on licensing Chinese commercialisation rights to Western rare disease and speciality medicines. The company, with its headquarters in London and offices in Beijing and Shanghai, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, CSP is rapidly becoming a ‘go-to’ trusted licensing partner, expanding its portfolio of innovative rare disease and ophthalmology assets while making business easier for companies wishing to develop and commercialize their products in China.

www.cspharmaceuticals.com

Contacts

CS Pharmaceuticals
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691